Frances M Weaver1,2, Brian Le3,4, Cara Ray1, Scott Miskevics1, Beverly Gonzalez1,5,6,7, Laura D Carbone3,4. 1. Center of Innovation for Complex Chronic Healthcare, Edward J. Hines, Jr. VA Hospital, Hines, Illinois, USA. 2. Public Health Sciences, Stritch School of Medicine, Loyola University, Maywood, Illinois, USA. 3. Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia, USA. 4. Department of Medicine, Division of Rheumatology, Medical College of Georgia at Augusta University, Augusta, Georgia, USA. 5. Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 6. Department of Biostatistics, University of Illinois, Chicago, Illinois, USA. 7. Department of Mathematics, Northeastern Illinois University, Chicago, Illinois, USA.
Abstract
Objective: To describe frequency and predictors of use of pharmacological therapies for osteoporosis in persons with a spinal cord injury (SCI).Design: Retrospective cohort study.Setting: United States Veterans Health Administration (VA) national databases.Participants: 11,048 persons with a traumatic SCI who received VA health care between Fiscal Years (FY) 2005-2015. Pharmacy data from VA's Corporate Data Warehouse were used to identify prescriptions for Food and Drug Administration-approved pharmacological treatments for osteoporosis including bisphosphonates, calcitonin, denosumab, raloxifene and teriparatide.Outcome Measures: Demographics, clinical and SCI-related characteristics, receipt of a dual energy x-ray absorptiometry (DXA), and prevalent lower extremity fractures were examined to determine factors related to receiving a pharmacological agent for osteoporosis. Results: 1,041 persons (9.4%) had a prescription for a pharmacological agent for osteoporosis; the majority (n = 964, 93.0%) were bisphosphonates. There was a significant decline in the number of these prescriptions from FY 2005 (13.0%) to FY 2015 (2.2%). In multivariable analysis, age (>50 years) (OR = 1.60, 95% CI 1.31-1.94); female sex (OR = 4.09, 95% CI 2.74-6.09); opioid (OR = 1.24, 95% CI 1.01-1.51) or corticosteroid (OR = 1.92, 95% CI 1.01-1.51) prescriptions; complete injury (OR = 1.26, 95% CI 1.04-1.53); receipt of a DXA scan (OR = 84.03, 95% CI 59.80-118.07) and prevalent fracture (OR = 5.43, 95% CI 4.13-7.15) were positive predictors. Black race (OR = 0.43, 95% CI 0.33-0.57) and obese BMI (OR = 0.59, 95% CI 0.45-0.76) were negative predictors.Conclusions: Prescriptions for osteoporosis medications for persons with a SCI declined in recent years. The strongest predictors for having filled these prescriptions were having had a DXA or a prevalent fracture.
Objective: To describe frequency and predictors of use of pharmacological therapies for osteoporosis in persons with a spinal cord injury (SCI).Design: Retrospective cohort study.Setting: United States Veterans Health Administration (VA) national databases.Participants: 11,048 persons with a traumatic SCI who received VA health care between Fiscal Years (FY) 2005-2015. Pharmacy data from VA's Corporate Data Warehouse were used to identify prescriptions for Food and Drug Administration-approved pharmacological treatments for osteoporosis including bisphosphonates, calcitonin, denosumab, raloxifene and teriparatide.Outcome Measures: Demographics, clinical and SCI-related characteristics, receipt of a dual energy x-ray absorptiometry (DXA), and prevalent lower extremity fractures were examined to determine factors related to receiving a pharmacological agent for osteoporosis. Results: 1,041 persons (9.4%) had a prescription for a pharmacological agent for osteoporosis; the majority (n = 964, 93.0%) were bisphosphonates. There was a significant decline in the number of these prescriptions from FY 2005 (13.0%) to FY 2015 (2.2%). In multivariable analysis, age (>50 years) (OR = 1.60, 95% CI 1.31-1.94); female sex (OR = 4.09, 95% CI 2.74-6.09); opioid (OR = 1.24, 95% CI 1.01-1.51) or corticosteroid (OR = 1.92, 95% CI 1.01-1.51) prescriptions; complete injury (OR = 1.26, 95% CI 1.04-1.53); receipt of a DXA scan (OR = 84.03, 95% CI 59.80-118.07) and prevalent fracture (OR = 5.43, 95% CI 4.13-7.15) were positive predictors. Black race (OR = 0.43, 95% CI 0.33-0.57) and obese BMI (OR = 0.59, 95% CI 0.45-0.76) were negative predictors.Conclusions: Prescriptions for osteoporosis medications for persons with a SCI declined in recent years. The strongest predictors for having filled these prescriptions were having had a DXA or a prevalent fracture.
Authors: Maya N Hatch; Jason Raad; Katie Suda; Kevin T Stroupe; Alice J Hon; Bridget M Smith Journal: Arch Phys Med Rehabil Date: 2018-02-06 Impact factor: 3.966
Authors: H Johansson; K Siggeirsdóttir; N C Harvey; A Odén; V Gudnason; E McCloskey; G Sigurdsson; J A Kanis Journal: Osteoporos Int Date: 2016-12-27 Impact factor: 4.507
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Leslie R Morse; Lora Giangregorio; Ricardo A Battaglino; Robert Holland; B Catharine Craven; Kelly L Stolzmann; Antonio A Lazzari; Sunil Sabharwal; Eric Garshick Journal: PM R Date: 2009-02-06 Impact factor: 2.298
Authors: Laura D Carbone; Amy S Chin; Stephen P Burns; Jelena N Svircev; Helen Hoenig; Michael Heggeness; Lauren Bailey; Frances Weaver Journal: J Bone Miner Res Date: 2014-02 Impact factor: 6.741
Authors: Kristie N Tu; Janette D Lie; Chew King Victoria Wan; Madison Cameron; Alaina G Austel; Jenny K Nguyen; Kevin Van; Diana Hyun Journal: P T Date: 2018-02
Authors: Michael W Yeh; Hui Zhou; Annette L Adams; Philip H G Ituarte; Ning Li; In-Lu Amy Liu; Philip I Haigh Journal: Ann Intern Med Date: 2016-04-05 Impact factor: 25.391